Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation

Blood

Volumn 115, Issue 11, 2010, Pages 2311-2318

  McDermott, David H ^a   Conway, Susan E ^b   Wang, Tao ^c   Ricklefs, Stacy M ^d   Agovi, Manza A ^e   Porcella, Stephen F ^d   Tran, Huong Thi Bich ^b   Milford, Edgar ^b   Spellman, Stephen ^f   Abdi, Reza ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Center for International Blood and Marrow Transplant Research (CIBMTR)   (United States)

^f NATIONAL MARROW DONOR PROGRAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 77950427009     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-237768     Document Type: Article

References (29)

1. Spellman S, Setterholm M, Maiers M, et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant. 2008;14(suppl 9):37-44.
2. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338(7):436-445.
3. McDermott DH, Murphy PM. Chemokines and their receptors in infectious disease. Springer Semin Immunopathol. 2000;22(4):393-415.
4. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000; 52(1):145-176. (Pubitemid 30127598)
5. Mapara MY, Leng C, Kim YM, et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant. 2006; 12(6):623-634. (Pubitemid 43758628)
6. Olsnes AM, Ersvaer E, Ryningen A, Bruserud O. Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. Hematology. 2008;13(6):329-332.
7. + T-cell-dendritic cell interaction. Nature. 2006;440(7086):890-895.
8. Reddy P, Arora M, Guimond M, Mackall CL. GVHD: a continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transplant. 2009;15(suppl 1):162-168.
9. Ueha S, Murai M, Yoneyama H, et al. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. J Leukoc Biol. 2007;81(1):176-185. (Pubitemid 46021267)
10. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versushost disease. J Clin Invest. 1999;104(1):49-57. (Pubitemid 29534344)
11. Terwey TH, Kim TD, Kochman AA, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005;106(9):3322-3330.
12. Kim DH, Jung HD, Lee NY, Sohn SK. Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. Transplantation. 2007;84(7):917-925.
13. Bogunia-Kubik K, Duda D, Suchnicki K, Lange A. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91(12): 1628-1634. (Pubitemid 46032960)
14. Bogunia-Kubik K, Jaskula E, Lange A. The presence of functional CCR5 and EBV reactivation after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40(2): 145-150. (Pubitemid 47046212)
15. Davies SM, Borowitz MJ, Rosner GL, et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111(6):2984-2990.
16. Loeffler J, Steffens M, Arlt EM, et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol. 2006;44(5): 1847-1850. (Pubitemid 43726281)
17. Salkowitz JR, Bruse SE, Meyerson H, et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol. 2003;108(3): 234-240. (Pubitemid 37117369)
18. Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol. 2000;12(9):1311-1318. (Pubitemid 30657775)
19. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352(9131):866-870.
20. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998;282(5395):1907-1911.
21. Knudsen TB, Kristiansen TB, Katzenstein TL, Eugen-Olsen J. Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression. J Med Virol. 2001;65(3):441-444. (Pubitemid 32959066)
22. Gonzalez E, Bamshad M, Sato N, et al. Racespecific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A. 1999;96(21):12004-12009. (Pubitemid 29502848)
23. Abdi R, Tran TB, Sahagun-Ruiz A, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol. 2002;13(3):754-758. (Pubitemid 34183942)
24. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923-1930. (Pubitemid 39297840)
25. Lee SJ, Klein J, Haagenson M, et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583.
26. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
27. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
29. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology. 2003;124(2):352-360. (Pubitemid 36169252)